Selected Publications: Jun - Dec 2016

Selected Publications: Jun - Dec 2016

 

  1. The emerging roles of exosomes in leukemogeneis. Oncotarget. 2016 May 12. Zhou J, Wang S, Sun K, Chng WJ.
  2. Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. Onco Targets Ther. 2016 May 30. 9:3187-95. Ang YL, Lim JS, Soo RA.
  3. Considerations regarding lipofilling in patients after breast cancer.
    J Plast Reconstr Aesthet Surg. 2016 May; 69(5):e103-4. Chan CW.
  4. Exosome-mediated metastasis: From epithelial-mesenchymal transition to escape from Iimmunosurveillance. Trends Pharmacol Sci. 2016 May; 37(7):606-17. Syn N, Wang L, Sethi G, Thiery JP, Goh BC.
  5. Local immune stimulation by intravesical instillation of baculovirus to enable bladder cancer therapy. Sci Rep. 2016 Jun 8; 6:27455. Ang WX, Zhao Y, Kwang T, Wu C, Chen C, Toh HC, Mahendran R, Esuvaranathan K, Wang S.
  6. Pharmacogenetics-guided phase I study of capecitabine on an intermittent schedule in patients with advanced or metastatic solid tumours. Sci Rep. 2016 Jun 14; 6:27826. Soo RA, Syn N, Lee SC, Wang L, Lim XY, Loh M, Tan SH, Zee YK, Wong AL, Chuah B, Chan D, Lim SE, Goh BC, Soong R, Yong WP.
  7. PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight. 2016 Jun 16; 1(9):e87607. Thura M, Al-Aidaroos AQ, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, Soo RA, Hong CW, Wang L, Lin SJ, Chen E, Rha SY, Chung HC, Li J, Nandi S, Yuen HF, Zhang SD, Guan YK, So J, Zeng Q.
  8. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016 Jun 21; 18(1):64. Zeng C, … Hartman M, … Zheng W et al.
  9. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nat Commun. 2016 Jun 21; 7:11702. Zhang WC, Chin TM, Yang H, Nga ME, Lunny DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR, Lim PX, Lee JZ, Tan BJ, Shyh-Chang N, Lim EH, Lim WT, Tan DS, Tan EH, Tai BC, Soo RA, Tam WL, Lim B.
  10. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl Acad Sci USA. 2016 Jun 28; 113(26):E3735-44. Mahara S, Lee PL, Feng M, Tergaonkar V, Chng WJ, Yu Q.
  11. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med. 2016 Jun; 22(6):666-71. Fukawa T, … Tan KK, … Shyh-Chang N et al
  12. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 June. Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P.
  13. An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Hum Mol Genet. 2016 Jul 11. Wyszynski A, … Hartman M, … Cole MD et al.
  14. Prevalence and predictors of bias in the reporting of primary efficacy and toxicity endpoints in randomized clinical trials of radiation oncology. J Med Imaging Radiat Oncol. 2016 Jul 11. Tan TH, Chen D, Soon YY, Tey JC.
  15. Molecular switch of EZH2 in hypoxia. Cell Cycle. 2016 Jul 26; 1-2. Mahara S, Chng WJ, Yu Q.
  16. High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer. Oncotarget. 2016 Jul 28. Wang T, Srivastava S, Hartman M, Buhari SA, Chan CW, Iau P, Khin LW, Wong A, Tan SH, Goh BC, Lee SC.
  17. Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence. Cancer Biol Ther. 2016 Jul; 17(7): 723–726. Abid MB, De Mel S, Abid MA, Tan KB, Chng WJ.
  18. Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. Cancer Discov. 2016 Jul; 6(9):1052-67. Kar SP, ... Lee SC, ...Lambrechts D et al.
  19. Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment. Sci Adv. 2016 Jul; 2 (7). Khoo BL, Grenci G, Jing T, Lim YB, Lee SC, Thiery JP, Han J, Lim CT.
  20. Operative method for transverse colon carcinoma: Transverse colectomy versus extended colectomy. Dis Colon Rectum. 2016 Jul; 59(7):630-9. Chong CS, Huh JW, Oh BY, Park YA, Cho YB, Yun SH, Kim HC, Lee WY.
  21. Thirty years of bone marrow transplantation in the Singapore General Hospital. Ann Acad Med Singapore. 2016 Jul; 45(7):315-7. Phipps C, Ho AY, Linn YC, Gopalakrishnan S, Ang AL, Lee JJ, Ng HY, Lim FW, Goh PS, Loh YS, Tan PH, Koh LP, Koh MB, Lee LH, Goh YT, Ong YW, Hwang WY.
  22. Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression. Sci Transl Med. 2016 Aug 3; 8(350): 350ra104. Yong KJ, ... Soo RA, ... Levantini E et al.
  23. Laparoscopic Anterior Resection with Transvaginal Specimen Extraction (TVSE) for Colorectal Cancer and Concomitant Total Hysterectomy and Bilateral Salpingo-Oophrectomy (THBSO): A Technical Description. Ann Surg Oncol. 2016 Aug 5. Tan CN, Chong CS, Fong YF, Rauff S, Tan KK.
  24. PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. Oncotarget. 2016 Aug 12. Teoh PJ, Bi C, Sintosebastian C, Tay LS, Fonseca R, Chng WJ.
  25. Anal adenocarcinoma presenting as a non-healing ischiorectal wound. J Gastrointest Surg. 2016 Aug 15. Chan DK, Tan KK.
  26. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Oncotarget. 2016 Aug 17. Franke NE, Kaspers GL, Assaraf YG, van Meerloo J, Niewerth D, Kessler FL, Poddighe PJ, Kole J, Smeets SJ, Ylstra B, Bi C, Chng WJ, Horton TM, Menezes RX, Musters RJ, Zweegman S, Jansen G, Cloos J.
  27. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood. 2016 Aug 18; 128(7):948-58. Yan J, Li B, Lin B, Lee PT, Chung TH, Tan J, Bi C, Lee XT, Selvarajan V, Ng SB, Yang H, Yu Q, Chng WJ.
  28. Manganese superoxide dismutase expression regulates the switch between an epithelial and a mesenchymal-like phenotype in breast carcinoma. Antioxid Redox Signal. 2016 Aug 20; 25(6):283-99. Loo SY, Hirpara JL, Pandey V, Tan TZ, Yap CT, Lobie PE, Thiery JP, Goh BC, Pervaiz S, Clément MV, Kumar AP.
  29. Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol. 2016 Aug 23; 3(1):e000095. Chang AY, Foo KF, Koo WH, Ong S, So J, Tan D, Lim KH.
  30. Fine-mapping of the 1p11.2 breast cancer susceptibility locus. PLoS One. 2016 Aug 24; 11(8):e0160316. Horne HN, … Hartman M, … Figueroa JD.
  31. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget. 2016 Aug 25. Wong AL, Sundar R, Wang TT, Ng TC, Zhang B, Tan SH, Soh T, Pang A, Tan CS, Ow S, Wang L, Mogro J, Ho JS, Jeyasekharan AD, Huang YQ, Thng CH, Chan CW, Hartman M, Iau P, Buhari SA, Goh BC, Lee SC.
  32. Does modern management of malignant extracranial disease prolong survival in patients with ≥3 brain metastases? World Neurosurg. 2016 Aug; 92:279-83. Karlsson B, Yamamoto M, Hanssens P, Beute G, Kawabe T, Koiso T, Söderman M, Lim K, Rosen CL, Yeo TT.
  33. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Expert Opin Drug Metab Toxicol. 2016 Aug; 12(8):911-22. Syn NL, Yong WP, Goh BC, Lee SC.
  34. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug; 17(8):e328-46. Kumar S, ... Chng WJ, ... Avet-Loiseau H et al.
  35. Dioxonaphthoimidazoliums are Potent and Selective Rogue Stem Cell Clearing Agents with SOX2-Suppressing Properties. ChemMedChem. 2016 Sep 6; 11(17):1944-55. Ho SH, Ali A, Ng YC, Lam KK, Wang S, Chan WK, Chin TM, Go ML.
  36. Administration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation. Antioxid Redox Signal. 2016 Sep 7. Cheah IK, Tang RM, Yew TS, Lim KH, Halliwell B.
  37. Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Sci Rep. 2016 Sep 7 ;6:32512. Darabi H, … Hartman M, … Lee SC, ... Dunning AM et al.
  38. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016 Sep 7; 7:12675. Lawrenson K, … Hartman M, … Gayther SA et al.
  39. Accelerated partial breast irradiation in an Asian population: dosimetric findings and preliminary results of a multicatheter interstitial program. Onco Targets Ther. 2016 Sep 8; 9:5561-6. Koh YV, Tan PW, Buhari SA, Iau P, Chan CW, Shen L, Tan SH, Tang JI.
  40. Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration? Biochem Biophys Res Commun. 2016 Sep 9; 478(1):162-7. Cheah IK, Feng L, Tang RM, Lim KH, Halliwell B.
  41. Proton therapy for early stage prostate cancer: is there a case? Onco Targets Ther. 2016 Sep 9; 9:5577-86. Chan TY, Tan PW, Tang JI.
  42. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. Singapore Med J. 2016 Sep 9. de Mel S, Chen Y, Gopalakrishnan SK, Ooi M, Teo C, Tan D, Teo ML, Tso AC, Lee LK, Nagarajan C, Goh YT, Chng WJ.
  43. Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. Int J Cancer. 2016 Sep 15; 139(6):1303-17. Shi J, … Hartman M, … Long J et al.
  44. Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation. Ann R Coll Surg Engl. 2016 Sep 23; 1-4. Parameswaran R, Shulin Hu J, Min En N, Tan WB, Yuan NK.
  45. Targeting SALL4 by entinostat in lung cancer. Oncotarget. 2016 Sep 26. Yong KJ, Li A, Ou WB, Hong CK, Zhao W, Wang F, Tatetsu H, Yan B, Qi L, Fletcher JA, Yang H, Soo RA, Tenen DG, Chai L.
  46. Quantitative Accuracy and Lesion Detectability of Low-Dose FDG-PET for Lung Cancer Screening. J Nucl Med. 2016 Sep 29. Schaefferkoetter JD, Yan J, Soderlund TA, Townsend DW, Conti M, Tam JK, Soo RA, Tham I.
  47. Asia prostate cancer study (A-CaP Study) launch symposium. Prostate Int. 2016 Sep; 4(3):88-96. Akaza H, … Chiong E, … Tsukamoto T et al
  48. Design and synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines. J Med Chem; 2016 Sep; 59(18):8233-62. Yang EG, Mustafa N, Tan EC, Poulsen A, Ramanujulu PM, Chng WJ, Yen JJ, Dymock BW.
  49. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016 Sep; 17(9):1240-7. Li Z, … Chng WJ, ... Bei JX et al.
  50. Long-term remission after low dose radiotherapy in patient with extensive squamous cell carcinoma of the hand: A case report. Medicine (Baltimore). 2016 Sep; 95(39):e5013. Cheo T, Ng I, Ooi KH, Ai Choo B.
  51. Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. Am J Hum Genet. 2016 Oct 6; 99(4):903-911. Ghoussaini M, … Hartman M, … Edwards SL et al.
  52. A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation. Cancer Lett. 2016 Oct 10; 381(1):49-57. Ong PS, Wang L, Chia DM, Seah JY, Kong LR, Thuya WL, Chinnathambi A, Lau JY, Wong AL, Yong WP, Yang D, Ho PC, Sethi G, Goh BC.
  53. Clinical Risk Stratification in Patients with Surgically Resectable Micropapillary Bladder Cancer. BJU Int. 2016 Oct 18. Fernandez M, … Chiong E, … Kamat AM et al.
  54. The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden. Breast Cancer Res. 2016 Oct 18; 18(1):105. Sackey H, Hui M, Czene K, Verkooijen H, Edgren G, Frisell J, Hartman M.
  55. Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer; a Prospective Multicenter Study. Clin Cancer Res. 2016 Oct 19. Zembutsu H, …, Hartman M, Chan CW, …, Nakamura Y.
  56. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan. Gastric Cancer. 2016 Oct 20. Kono K, Yong WP, Okayama H, Shabbir A, Momma T, Ohki S, Takenoshita S, So J.
  57. Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia. BMC Cancer. 2016 Oct 21; 16(1):820. Miao H, Hartman M, Verkooijen HM, Taib NA, Wong HS, Subramaniam S, Yip CH, Tan EY, Chan P, Lee SC, Bhoo-Pathy N.
  58. ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. Gastroenterology. 2016 Oct; 151(4):637-650.e10. Chan TH, …, So J, …, Chen L et al.
  59. Capecitabine pharmacogenetics: historical milestones and progress toward clinical implementation. Pharmacogenomics. 2016 Oct; 17(15):1607-1610. Syn N, Lee SC, Goh BC, Yong WP.
  60. Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study. Int J Hematol. 2016 Oct. 104(4):454-61. Chuncharunee S, Wong R, Rojnuckarin P, Chang CS, Chang KM, Lu MY, Hwang WL, Koh LP, Chen TY, Leung AY, Norasetthada L, Wang SC, Chang MC, Wu KH, Issaragrisil S.
  61. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. Ther Adv Respir Dis. 2016 Oct; 10(5):444-54. Lim JS, Soo RA.
  62. Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomas. Oncotarget. 2016 Nov; Hirpara JL, Loh T, Ng SB, Chng WJ, Pervaiz S.
  63. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients. 2016 Nov; Thongprasert S, Yang PC, Lee JS, Soo RA, Gruselle O, Myo A, Louahed J, Lehmann FF, Brichard VG, Coche T.